ALK-Abelló A/S/DKr ALK B
08:00
10:00
12:00
13:55
15:55
1D1W1MYTD1Y5YMAX
About ALK-Abelló A/S
ALK-Abelló A/S is a pharmaceutical company engaged in the development and production of allergy immunotherapy products. Based in Hørsholm, Denmark, the company specializes in allergy treatments that include tablets, injections, and drops targeting common allergens such as grass, tree, and ragweed pollen, as well as house dust mites. Established in the early 20th century, ALK-Abelló has expanded its operations to serve markets globally, with a particular focus on Europe and North America. Its strategic advantage lies in its strong research capabilities and a comprehensive portfolio of allergy treatment options. The company's ongoing investment in innovation supports its goal to transform the treatment of allergies worldwide.
Ticker
DKr ALK B
Sector
Primary listing
CSE
Employees
2,613
Headquarters
Horsholm, Denmark
Website
ALK-Abelló A/S Metrics
BasicAdvanced
kr 46B
38.56
kr 5.40
0.60
-
Price and volume
Market cap
kr 46B
Beta
0.6
52-week high
kr 237.60
52-week low
kr 131.40
Average daily volume
205K
Financial strength
Current ratio
3.381
Quick ratio
1.941
Long term debt to equity
5.508
Total debt to equity
6.486
Interest coverage (TTM)
53.68%
Profitability
EBITDA (TTM)
1,900
Gross margin (TTM)
67.24%
Net profit margin (TTM)
18.96%
Operating margin (TTM)
26.36%
Effective tax rate (TTM)
26.79%
Revenue per employee (TTM)
kr 2,420,000
Management effectiveness
Return on assets (TTM)
12.02%
Return on equity (TTM)
20.26%
Valuation
Price to earnings (TTM)
38.556
Price to revenue (TTM)
7.307
Price to book
7.2
Price to tangible book (TTM)
9.91
Price to free cash flow (TTM)
31.655
Free cash flow yield (TTM)
3.16%
Free cash flow per share (TTM)
6.577
Growth
Revenue change (TTM)
14.00%
Earnings per share change (TTM)
46.74%
3-year revenue growth (CAGR)
11.85%
10-year revenue growth (CAGR)
9.41%
3-year earnings per share growth (CAGR)
52.92%
10-year earnings per share growth (CAGR)
11.94%
10-year dividend per share growth (CAGR)
20.40%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.
Capital at risk
Upcoming events
FAQs
What’s the current market cap for ALK-Abelló A/S stock?
ALK-Abelló A/S (ALK B) has a market cap of DKr46B as of March 16, 2026.
What is the P/E ratio for ALK-Abelló A/S stock?
The price to earnings (P/E) ratio for ALK-Abelló A/S (ALK B) stock is 38.56 as of March 16, 2026.
Does ALK-Abelló A/S stock pay dividends?
No, ALK-Abelló A/S (ALK B) stock does not pay dividends to its shareholders as of March 16, 2026.
When is the next ALK-Abelló A/S dividend payment date?
ALK-Abelló A/S (ALK B) stock does not pay dividends to its shareholders.
What is the beta indicator for ALK-Abelló A/S?
ALK-Abelló A/S (ALK B) has a beta rating of 0.6. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.